GH Research (NASDAQ:GHRS) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of GH Research (NASDAQ:GHRS) in a research report sent to investors on Thursday morning, Marketbeat reports. The brokerage issued an overweight rating and a $14.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a research note on Monday, January 27th. Canaccord Genuity Group dropped their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

GH Research Trading Up 2.2 %

Shares of GHRS stock opened at $14.31 on Thursday. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The company has a market cap of $744.55 million, a PE ratio of -18.11 and a beta of 0.93. The company’s fifty day simple moving average is $9.49 and its 200-day simple moving average is $9.11.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Geode Capital Management LLC increased its holdings in GH Research PLC (NASDAQ:GHRS) by 4.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 72,513 shares of the company’s stock after buying an additional 3,092 shares during the period. Geode Capital Management LLC owned about 0.14% of GH Research worth $508,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).